Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man
暂无分享,去创建一个
C. Lien | H. Sunaga | P. Heerdt | J. Malhotra | J. Savarese | J. Owen | M. Murrell | D. Godfrey | P. Savard | M. Steinkamp
[1] H. Sunaga,et al. Preclinical Pharmacology of CW002: A Nondepolarizing Neuromuscular Blocking Drug of Intermediate Duration, Degraded and Antagonized by l-cysteine—Additional Studies of Safety and Efficacy in the Anesthetized Rhesus Monkey and Cat , 2016, Anesthesiology.
[2] P. Heerdt,et al. Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits. , 2014, Journal of the American Association for Laboratory Animal Science : JAALAS.
[3] C. Lien,et al. Neuromuscular dose-response studies: determining sample size. , 2011, British Journal of Anaesthesia.
[4] H. Sunaga,et al. Rapid Chemical Antagonism of Neuromuscular Blockade by l-Cysteine Adduction to and Inactivation of the Olefinic (Double-bonded) Isoquinolinium Diester Compounds Gantacurium (AV430A), CW 002, and CW 011 , 2010, Anesthesiology.
[5] C. Lien,et al. Determining the potency of neuromuscular blockers: are traditional methods flawed? , 2010, British journal of anaesthesia.
[6] Edward J Yoon,et al. Cysteine Reversal of the Novel Neuromuscular Blocking Drug CW002 in Dogs: Pharmacodynamics, Acute Cardiovascular Effects, and Preliminary Toxicology , 2010, Anesthesiology.
[7] H. Sunaga,et al. Pharmacodynamics and Cardiopulmonary Side Effects of CW002, a Cysteine-reversible Neuromuscular Blocking Drug in Dogs , 2010, Anesthesiology.
[8] H. Sunaga,et al. Gantacurium and CW002 Do Not Potentiate Muscarinic Receptor-mediated Airway Smooth Muscle Constriction in Guinea Pigs , 2010, Anesthesiology.
[9] C. Lien,et al. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. , 2009, Journal of critical care.
[10] L. Skovgaard,et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision , 2007, Acta anaesthesiologica Scandinavica.
[11] Harvey J. Motulsky,et al. Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate , 2006, BMC Bioinformatics.
[12] I. Pollock,et al. Plasma histamine and clinical tolerance to infused histamine in normal, atopic and urticarial subjects , 1991, Agents and Actions.
[13] Sanjay S. Patel,et al. Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat: A Comparison with Mivacurium , 2004, Anesthesiology.
[14] Sanjay S. Patel,et al. Clinical Pharmacology of GW280430A in Humans , 2004, Anesthesiology.
[15] P. Heerdt,et al. Cardiopulmonary Effects of the Novel Neuromuscular Blocking Drug GW280430A (AV430A) in Dogs , 2004, Anesthesiology.
[16] J. A. Ray,et al. Stereocontrolled synthesis of cis-dibenzoquinolizine chlorofumarates: curare-like agents of ultrashort duration. , 2001, The Journal of organic chemistry.
[17] E. Martin,et al. Rocuronium potency and recovery characteristics during steady-state desflurane, sevoflurane, isoflurane or propofol anaesthesia. , 2000, British journal of anaesthesia.
[18] J. A. Ray,et al. Synthesis of ultra-short-acting neuromuscular blocker GW 0430: a remarkably stereo- and regioselective synthesis of mixed tetrahydroisoquinolinium chlorofumarates. , 1999, Organic letters.
[19] J. A. Ray,et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. , 1999, Journal of medicinal chemistry.
[20] R. Mirakhur,et al. Neuromuscular Effects of Rocuronium During Sevoflurane, Isoflurane, and Intravenous Anesthesia , 1998, Anesthesia and analgesia.
[21] T. Ledowski,et al. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia , 1998, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[22] T. Ledowski,et al. Augmentation of the neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane or total i.v. anaesthesia. , 1998, British journal of anaesthesia.
[23] C. Lien,et al. Importance of the Organ-Independent Elimination of Cisatracurium , 1996, Anesthesia and analgesia.
[24] D. Smith,et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. , 1996, British journal of anaesthesia.
[25] J. van Egmond,et al. Effect of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pancuronium and atracurium. , 1996, British journal of anaesthesia.
[26] Fisher Dm,et al. A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. , 1986 .
[27] D. Fisher,et al. A Pharmacokinetic Explanation for Increasing Recovery Time Following Larger or Repeated Doses of Nondepolarizing Muscle Relaxants , 1986, Anesthesiology.
[28] L B Sheiner,et al. Elimination of Atracurium in Humans: Contribution of Hofmann Elimination and Ester Hydrolysis versus Organ‐based Elimination , 1986, Anesthesiology.
[29] D. Metcalfe,et al. Measurement of plasma histamine: description of an improved method and normal values. , 1982, The Journal of allergy and clinical immunology.
[30] J. Shelhamer,et al. Effects of infused histamine: correlation of plasma histamine levels and symptoms. , 1982, The Journal of allergy and clinical immunology.